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Results Glycocholic acid, N-palmitoyl glutamic acid and 
hexanoylcarnitine were identified as single markers dis-
criminating PDAC and CP by univariate analysis. OPLS-
DA resulted in a panel of five metabolites including the 
aforementioned three metabolites as well as phenylacetyl-
glutamine (PAGN) and chenodeoxyglycocholate.
Conclusion Using LC-MS-based metabolomics we iden-
tified three single metabolites and a five-metabolite panel 
discriminating PDAC and CP in two independent cohorts. 
Although further study is needed in larger cohorts, the 
metabolites identified are potentially of use in PDAC 
diagnostics.
Keywords Pancreatic cancer · Pancreatic ductal 
adenocarcinoma · Pancreatitis · Metabolomics · 
Metabolism · LC-MS · Biomarkers · Serum · Plasma · 
Discovery · Validation
Abbreviations
RPLC-MS  Reversed phase liquid chromatography cou-
pled to mass spectrometry
PDAC  Pancreatic ductal adenocarcinoma
CP  Chronic pancreatitis
OPLS-DA  Orthogonal partial least squares discriminant 
analysis
1 Introduction
Pancreatic ductal adenocarcinoma (PDAC) is the fourth 
most common cause of cancer-related death with a 5-year 
survival rate of <5% (Siegel et  al. 2016). In contrary to 
many other forms of cancer the incidence of PDAC is ris-
ing and predicted to become the 2nd most common cause 
of cancer-related death by 2030 (Rahib et  al. 2014). Its 
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lethality can be attributed to late diagnosis, almost com-
plete resistance to conventional chemo- and radiotherapy, 
and a lack of diagnostic biomarkers. Unlike breast or colo-
rectal cancer, the only treatment with curative intent is 
surgery, for which < 20% of patients qualify; but even then 
the chance of survival is very low (Lohr 2006). Therefore, 
PDAC should be treated as a medical emergency (Lohr 
2014). Risk factors for PDAC include chronic pancreatitis 
(CP) and around 5% of CP patients develop PDAC over 
time (Pinho et  al. 2014; Garrido-Laguna and Hidalgo 
2015). Both PDAC and CP are characterized by an exces-
sive and reactive stroma, or desmoplasia, which makes it 
difficult to distinguish between the two conditions (Kloppel 
and Adsay 2009). The one FDA-approved biomarker for 
PDAC, carbohydrate antigen 19-9 (CA 19-9), is only useful 
for prognosis and detection of disease recurrence (Fong and 
Winter 2012). Therefore there is an urgent clinical need of 
a non-invasive diagnostic biomarker for PDAC.
Metabolomics is the untargeted analysis of low molecu-
lar weight endogenous compounds, metabolites, present in 
e.g. a defined biological sample such as tissue or a bodily 
fluid as blood (Fiehn et al. 2000; Fiehn 2002; Spratlin et al. 
2009; Dunn et al. 2011). The most widely used analytical 
platform for metabolomics providing the largest metabo-
lome coverage is liquid chromatography-mass spectrom-
etry (LC-MS) (Want et al. 2007; Patti et al. 2012; Yin and 
Xu 2014). Given the established connection between cell 
metabolism and cancer (Hanahan and Weinberg 2011), 
LC-MS metabolomics has been applied to identify metab-
olite markers for several cancers (Spratlin et  al. 2009; 
Nordstrom and Lewensohn 2010; Nicholson et  al. 2012), 
including PDAC (Daemen et  al. 2015; Rios Peces et  al. 
2016). Specifically, there have been previous LC-MS based 
metabolomics efforts to compare PDAC and CP blood sam-
ples (Urayama et al. 2010; Fukutake et al. 2015). There is 
however still no screening test for PDAC available.
In the present study, we have performed LC-MS based 
metabolomics on blood samples to compare the metabolic 
profiles of PDAC and CP in two independent cohorts. Both 
single discriminative metabolites and a panel of metabo-
lites discriminating PDAC and CP were identified. Our 
findings have potential clinical relevance for early diagnosis 
of PDAC among CP patients to improve patient survival.
2  Materials and methods
2.1  Clinical samples
The study comprised a discovery- and a validation cohort 
(Table  1). All patients had given informed consent in 
accordance with the Helsinki Declaration (World Med 
2013).
Blood samples for the discovery cohort were collected 
from German patients with PDAC (n = 44) and patients 
with CP (n = 23). Serum samples were prepared at the same 
location using a standardized protocol.
The validation cohort included Swedish PDAC patients 
(n = 20) and CP patients (n = 31). Plasma samples were 
supplied by the Karolinska Institutet biobank and had been 
prepared at different sites following a standardized proce-
dure: whole blood samples were obtained at fasting early in 
the morning, collected in sodium citrate tubes and immedi-
ately placed in −80 °C.
All plasma and serum samples were stored at −80 °C at 
all times prior to analysis.
2.2  Sample preparation
All solvents used below were of HPLC grade (Fisher 
Chemicals) and the water was Milli-Q (Millipore).
Plasma and serum samples were thawed on ice and 
50 µl aliquots were mixed with 150 µl MeOH for protein 
precipitation. Samples were then centrifuged for 15 min at 
15800×g. The supernatant was transferred to a new tube 
and then evaporated to complete dryness in a vacuum con-
centrator. Prior to LC-MS analysis, samples were recon-
stituted in 50  µl MeOH:H2O 1:1 and the two isotopically 
labelled internal standards phenylalanine (D5) and palmitic 
acid (D4) (Cambridge Isotope Laboratories) were added at 
a final concentration of 5 µM.
2.3  LC-MS analysis
Metabolites were separated by reversed phase liquid chro-
matography and detected by electrospray ionization (ESI) 
mass spectrometry in positive mode. All samples were run 
in randomized order, randomized by the random number 
function in Excel (Microsoft, USA).
For the discovery cohort, the analytical platform con-
sisted of a 1200 HPLC-system (Agilent) connected on-line 
to an LTQ Orbitrap Velos equipped with a HESI probe 
(Thermo Scientific). 5 µl of each sample were injected onto 
Table 1  Clinical data
a n = 41,
b n = 42
Discovery cohort Validation cohort
PDAC CP PDAC CP
Subjects (n) 44 23 20 31
Male/female 
ratio
21/20a 18/5 10/10 16/15
Age, median 
(range)
67 (30–102)b 36 (31–93) 70 (46–80) 69 (23–87)
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a Kinetex C18 150 × 2.1 mm column, 2.6 µ, 100 Å (Phe-
nomenex) and the following mobile phases were used at 
a flow rate of 0.4 ml/min:  H2O with 0.1% formic acid (A) 
and 3:1 acetonitrile:isopropanol with 0.1% formic acid (B). 
The linear gradient was 0 min, 5% B; 1 min, 5% B; 21 min, 
95% B; 26 min, 95% B; 26.5 min, 5% B; 33 min, 5% B. MS 
data was collected in centroid mode between m/z 80-1200 
at an Orbitrap resolution of 60,000 using the following ESI 
settings: Cap Temp, 350; Sheath Gas Flow, 45; Aux Gas 
Flow, 15; Source Voltage, 3 kV; S-Lens RF Level, 60%.
For the validation cohort, the analytical platform con-
sisted of a 1290 UHPLC-system (Agilent) connected on-
line to a 6550 Q-ToF equipped with a JetStream source 
(Agilent). 5 µl of each sample were injected onto a Kine-
tex C18 100 × 2.1 mm column, 2.6 µ, 100 Å (Phenomenex) 
and the following mobile phases were used at a flow rate 
of 0.5  ml/min: H2O with 0.1% formic acid (A) and 3:1 
acetonitrile:isopropanol with 0.1% formic acid (B). The lin-
ear gradient was 0 min, 5% B; 7 min, 95% B; 9 min, 95% 
B; 9.2 min, 5% B; 11 min, 5% B. MS data was collected 
in centroid mode between m/z 70-1700 using the following 
ESI settings: Gas Temp, 300; Gas Flow, 8; Nebulizer Pres-
sure, 40; Sheet Gas Temp, 350; Sheet Gas Flow, 11; Vcap, 
4000; Fragmentor, 100; Skimmer1, 45; OctapoleRFPeak, 
750. The analysis procedure has also been described previ-
ously (Staubert et al. 2015; Lindahl et al. 2016).
The peak heights for the internal standards were contin-
uously monitored during analysis to ensure MS signal sta-
bility (Supplementary table 1). In the validation cohort the 
signal stability was monitored by injection of a pooled QC 
sample for every sixth sample during the LC-MS analysis. 
Examples of extracted ion chromatograms are illustrated in 
Supplementary Fig. 1.
Targeted MS/MS data of a pooled sample was also col-
lected for identification purposes of discriminative features 
in both cohorts using the ESI settings described above 
(Supplementary Fig. 2). Samples were analyzed on two dif-
ferent instruments for reasons of instrument availability at 
the time of receiving the different cohorts to the laboratory.
2.4  Discovery cohort data preprocessing
Discovery raw data files were converted to .cdf format using 
the file converter tool in Xcalibur version 2.2 (Thermo Sci-
entific). Peak detection, integration and alignment were 
performed with the open-source software XCMS version 
1.30.3 (Smith et  al. 2006). The following XCMS settings 
were used: For peak detection and integration with the cent-
Wave algorithm, ppm = 10, snthr = 5, peakwidth = c(5.15), 
mzdiff = −0.01, prefilter = c(6,100), fitgauss = TRUE; for 
alignment with Obiwarp, distFunc = “cor”, profStep = 1, 
grouping parameters bw = 1, mzwid = 0.005, minfrac = 0.5. 
Isotopes and adducts were not removed.
Sample-wise median normalization (Trezzi et al. 2015) 
was used to correct for technical variation in e.g. sam-
ple preparation and MS signal intensity. Next, a two-step 
peak filtering approach was applied. First, peaks with 
an intensity level ≥ 60,000 were retained. Second, only 
peaks present in at least 75% of samples in at least one 
group were used for the following statistical analyses.
2.5  Univariate analysis
Both univariate and multivariate statistical analysis were 




























Fig. 1  Schematic overview of data analysis workflow. Univari-
ate (left) and multivariate (right) analyses comparing PDAC and CP 
were performed in parallel, starting with the abundance filtered dis-
covery cohort data set (step 1). The large number of metabolite fea-
tures (n = 4578) is due to superfluous features e.g. adducts and iso-
topes. Following statistical analysis of the discovery cohort (step 2a 
and b), selected metabolite features were examined manually in the 
raw data and low quality features (e.g. adducts, isotopes, low inten-
sity peaks) were excluded (step 3). High quality features that were 
not present in the validation cohort were excluded as well, together 
with features that could not be identified. The discriminative capacity 
of the remaining identified features, now referred to as metabolites, 
was confirmed in the validation cohort by statistical analysis (step 4a 
and b). Finally, metabolites that were regulated in opposite directions 
in the two cohorts were excluded (step 5), resulting in three single 
metabolite markers and a panel of five metabolite markers
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Univariate analysis was performed in the software 
GraphPad Prism version 6.07 (GraphPad), where PDAC 
and CP were compared using a Student’s t test with 
Welch’s correction. In the discovery cohort, metabolite fea-
tures with p-value > 0.05 were excluded in order to limit the 
number of features to be examined in the raw data.
Box plots and bar graphs were created in GraphPad 
Prism.
2.6  Multivariate analysis
For multivariate analysis, data sets were imported into the 
software SIMCA version 14 (Umetrics). Unit variance scal-
ing was applied to give metabolite features with low and 
high variation between samples equal importance, and log 
transformation was applied to shift data towards Gaussian 
distribution. Principal component analysis (PCA) was ini-
tially applied to all variables extracted using XCMS (Sup-
plementary Fig.  3). Subsequently was orthogonal partial 
least squares-discriminant analysis (OPLS-DA) (Bylesjo 
et al. 2006) with default SIMCA settings was used to iden-
tify metabolite feature patterns discriminating PDAC and 
CP. The features with the highest discriminatory power 
between classes were selected based on the variable impor-
tance for the projection (VIP) plot. Features significant 
with a 95% confidence interval, based on the cross- valida-
tion, were selected for further analysis. For the discovery 
cohort, the feature selection was done in the same way with 
the additional criterion that the VIP-values should be >1.5.
For refined OPLS-DA models, i.e. those built on 
selected metabolite features only, cross-validation settings 
were changed from the default 1/7 to 1/5 of samples con-
stituting the internal prediction set. The purpose was to 
minimize the bias of the refined model towards the selected 
metabolite features.
All score- and loading scatter plots were created in 
SIMCA.
2.7  Feature quality control
The discriminative metabolite features selected in the dis-
covery cohort had to meet several criteria to ensure feature 
quality, regardless of the method of statistical analysis. 
First, features were manually examined in the raw data. Iso-
topes, adducts and poor quality features, e.g. low intensity 
peaks were excluded following manual inspection of peak 
shape. This removed features judged by the software to be 
chromatographic peaks, but which they human eye rapidly 
can assign to be column bleed or similar artefacts. Second, 
for the univariate part of the analysis workflow, features 
were re-integrated in the raw data using the Qual and Quan 
Browsers in Xcalibur version 2.2 (Thermo Scientific) and 
their statistical significance was confirmed with a Student´s 
t test (p < 0.05). Third, ion chromatograms of the selected 
features were extracted from the validation cohort raw data 
files using the software MassHunter Qual version B.06.00 
(Agilent); discovery cohort features that were either not 
detected or of low quality in the validation cohort were 
excluded. Fourth, unidentifiable metabolite features were 
excluded.
Peak areas of the identified metabolites that met quality 
control criteria were integrated in the validation cohort raw 
data files using the “Agile” setting in MassHunter Qual. 
The median normalized peak area values were used for fur-
ther uni- and multivariate analyses to confirm the results 
from the discovery cohort.
2.8  Metabolite identification
Accurate mass measurements were subject to database 
searches in the public databases METLIN (Smith et  al. 
2005) and Human Metabolome Database (Wishart et  al. 
2013) as well as an in-house library comprising 384 syn-
thetic standards. Database hits were then confirmed by 
retention time match (in-house library only) and MS/
MS spectral match from pooled samples (Supplementary 
Fig. 2). In a few cases additional synthetic standard com-
pounds were acquired and analyzed on the same platform 
to confirm compound identity.
For the discovery cohort, samples were also fractionated 
by LC and relevant fractions were then analyzed by direct 
infusion to acquire  MSn structural information (van der 
Hooft et al. 2012).
3  Results
3.1  Univariate analysis identifies three single 
metabolites discriminating PDAC and CP
After abundance peak filtering, the discovery cohort data 
set contained 4578 metabolite features including iso-
topes, adducts and low quality features (Fig.  1). 254 of 
these features had a p-value < 0.05 as determined by Stu-
dent’s t test  with Welch’s correction. After (i) raw data 
examination, (ii) re-integration and confirmation of sta-
tistical significance, (iii) detection in validation cohort 
and (iv) feature identification, 17 metabolites remained. 
11 of these metabolites had a p-value < 0.05 (Student’s t 
test) in the validation cohort as well. Fold-change calcu-
lations showed that the eight metabolites with the low-
est intensity were down-regulated in PDAC compared to 
CP in the discovery cohort, as opposed to up-regulated in 
PDAC compared to CP in the validation cohort (Fig. 2). 
These eight metabolites were phospholipids. After 
exclusion of the phospholipids, the three metabolites 
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glycocholic acid, hexanoylcarnitine and N-palmitoyl glu-
tamic acid remained as single discriminative markers for 
PDAC compared to CP (Fig. 3). In the discovery cohort, 
applying an FDR cut-off of 5% to the 254 metabolites did 
not yield any significant metabolites. However the man-
ual inspection and re-integration together with the vali-
dation in an independent patient cohort strengthens the 
findings.
3.2  Multivariate analysis identifies a panel of five 
metabolites discriminating PDAC and CP
259 of the 4578 metabolite features in the discovery cohort 
(Fig.  1, step 2b) were selected as potential markers for 
PDAC as determined by the VIP-plot in the initial OPLS-
DA model (Fig. 4a). 19 metabolites remained after feature 
quality control, detection in validation cohort and metabo-
lite identification. These 19 metabolites were significant in 
the validation cohort OPLS-DA model (Fig.  4b). A com-
parison of the loading scatter plots for the discovery- and 
validation cohort OPLS-DA models showed that a group of 
14 metabolites was regulated in opposite directions in the 
two cohorts (Fig. 4c, d). As in the univariate analysis, all 
14 were phospholipids that were down-regulated in PDAC 
compared to CP in the discovery cohort but up-regulated in 
PDAC in the validation cohort.
After exclusion of the phospholipids the five metabolites 
N-palmitoyl glutamic acid, glycocholic acid, hexanoylcar-
nitine, chenodeoxyglycocholate and PAGN remained. They 
were used to build a refined validation cohort OPLS-DA 
model (Fig.  5a, b) to evaluate their discriminatory power 
in the absence of phospholipids. The predictive ability of 
the refined model as indicated by the Q2(cum) value was 
0.513, i.e. approximately 50% of samples were correctly 
classified, and the R2X(cum) value was 0.736. The statis-
tical significance of the model as indicated by cross-vali-
dated ANOVA was p = 8.2E−07.
4  Discussion
The PDAC incidence rate is expected to increase world-
wide over the next years (Rahib et  al. 2014), making the 
need for improved diagnostic tools even more acute. One 
group at risk of PDAC development is CP patients (Pinho 
et al. 2014) who would clearly benefit from the discovery 
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Fig. 2  Fold-change comparison between cohorts. Following confir-
mation of metabolite significance in the validation cohort (Fig. 1, step 
4a and b), fold-change calculations revealed that eight metabolites 
were regulated in opposite directions in the discovery- and validation 
cohorts. All eight metabolites were phospholipids that were down-
regulated in PDAC compared to CP in the discovery cohort, but up-
regulated in PDAC compared to CP in the validation cohort. Conse-



































N-palmitoyl glutamic acidGlycocholic acidHexanoylcarnitine
Fig. 3  Single metabolite markers discriminating PDAC and CP. 
After identification of significant features in the discovery cohort 
(n = 67), feature quality control and confirmation of significance in 
the validation cohort (n = 51), three single metabolite markers for 
PDAC compared to CP remained. All three were up-regulated in 
PDAC. Statistical test: Welch’s unequal variances t test. Box plot set-
tings: Range, minimum to maximum value; line at median
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Any preclinical biomarker study at the discovery stage 
should include an inflammatory control of the target organ 
to increase the chance of identifying disease-specific mark-
ers (Chechlinska et  al. 2010; Lindahl et  al. 2016). Here, 
CP serves as an inflammatory control of the pancreas for 
PDAC-specific marker discovery. In addition, CP is a risk 
factor for PDAC development and the two diseases share 
several inflammatory parameters. It is therefore imperative 
to identify PDAC-unique markers specific for the discrimi-
nation of PDAC and CP.
In the present study, we have compared the metabolic 
profiles of PDAC and CP in blood in two independent 
cohorts using untargeted LC-MS. The fact that both cohorts 
did not consist of either serum or plasma is a drawback of 
the study. However, that they represent completely inde-
pendent patients strengthens the validity of the proposed 
biomarkers. Previous reports comparing the metabolite 
profiles of serum and plasma samples have found good cor-
relation between the two sample matrices (Denery et  al. 
2011; Yu et al. 2011; Ishikawa et al. 2014). We have iden-
tified three single discriminative metabolites as well as a 
five-metabolite panel of markers, since a marker panel can 
increase specificity and sensitivity compared to single dis-


































Fig. 4  Reversed metabolite fold-change direction in discovery- and 
validation cohorts. a Score scatter plot for the initial OPLS-DA model 
of 4578 metabolite features in the discovery cohort (Fig. 1, step 2b). 
Blue dots represent PDAC samples (scores, n = 44); white dots repre-
sent CP samples (n = 23); t1 on the x-axis, first component; to1 on the 
y-axis, first of two orthogonal components. Model parameters: CV-
groups, 7; R2X(cum) 0.39; Q2(cum) 0.22; CV-ANOVA p = 0.02. The 
model was used to select 259 features for further analysis. b Score 
scatter plot for the OPLS-DA model in the validation cohort based on 
the 19 metabolites remaining from the discovery cohort (Fig. 1, step 
4b). Orange dots represent PDAC samples (n = 20); white dots repre-
sent CP samples (n = 31); to1 on the y-axis, first (and only) orthogo-
nal component. Model parameters: CV-groups, 7; R2X(cum) 0.648; 
Q2(cum) 0.699; CV-ANOVA p = 1.7E-11. c Loading (metabolite) 
scatter plot for the discovery cohort OPLS-DA model. The phospho-
lipids are situated to the right of the vertical line, close to the dummy 
CP variable, indicating that they are down-regulated in PDAC com-
pared to CP. d Loading scatter plot for the validation cohort OPLS-
DA model. The phospholipids are situated to the left of the vertical 
line, close to the dummy PDAC variable; hence they are up-regulated 
in PDAC compared to CP. Based on this reversal of their fold-change 
directions, the 14 phospholipids were excluded from the final metabo-
lite marker panel
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2012). All five metabolites identified here can be easily 
measured in a clinical MS-lab.
PDAC and CP blood samples have been compared by 
LC-MS metabolomics analysis in two previous studies 
(Urayama et al. 2010; Fukutake et al. 2015). One of these 
targeted free amino acids in plasma. The advantage of a 
targeted approach is that sample preparation and analysis 
is optimized for a specific class of metabolites, but at the 
cost of covering only a limited part of the metabolome. 
Untargeted LC-MS on the other hand has the largest poten-
tial to identify novel metabolites due to increased metabo-
lome coverage (Patti et  al. 2012). In the second previous 
study comparing PDAC and CP, untargeted LC-MS was 
applied to plasma samples. Contrary to the present study, 
clinical data on e.g. disease stage and smoking status was 
available, which is important to avoid known confounding 
factors; however, the sample size (n = 10) was very limited 
which makes the results less generalizable. Other studies 
have applied different analytical metabolomics platforms 
to discriminate PDAC and CP in bodily fluids. In a study 
using gas chromatography-mass spectrometry, a majority 
of the serum discriminative metabolites were amino acids 
(Kobayashi et  al. 2013), but included also some metabo-
lites that would not have been particularly well captured in 
our LC-MS set-up such as some sugar species including, 
arabinose, ribulose and 1,5-Anhydro-D-glucitol and some 
organic acids such as uric acid, nonanoic acid and caprylic 
acid. In the mentioned study, CP samples were however 
included in the validation cohort only. Amino acids were 
also connected to future risk of pancreatic cancer in a 
metabolomics study applying LC-MS to prediagnostic 
plasma (Mayers et  al. 2014). In the present study a num-
ber of amino acids were found dysregulated in PDAC com-
pared to CP in the validation cohort only (data not shown), 
but lacking confirmation in a second cohort these results 
were excluded. Further, two studies have used nuclear 
magnetic resonance to study plasma and urine samples, 
respectively, but have not validated their results in a second 
cohort (Zhang et  al. 2012) or had only three CP samples 
out of a total of 25 samples included in the benign control 
group (Davis et al. 2013).
In the present study, the levels of a number of phos-
pholipids were altered in PDAC compared to CP in both 
cohorts. Phospholipids were also found dysregulated in 
previous studies (Urayama et al. 2010; Ritchie et al. 2013; 
Sakai et  al. 2016). However, we excluded all phospholip-
ids as potential markers since they were down-regulated in 
PDAC in the discovery cohort as opposed to up-regulated 
in the validation cohort (Figs. 2, 4c, d). A possible explana-
tion for these results is that different blood sample matrices, 
i.e. serum and plasma, were used in the two cohorts. Serum 
and plasma samples from the same individual are known to 
display different concentration levels for some metabolites, 
including phospholipids, due to the differences in sample 
handling (Yu et  al. 2011). Noteworthy, as systemic phos-
pholipid levels are altered by inflammatory responses in 
general, they are unlikely candidates for disease specific 
markers (Lindahl et al. 2016).
As mentioned above, the two bile acids glycocholic acid 
and chenodeoxyglycocholate were significantly increased 
in PDAC compared to CP in the present study (Figs. 3, 5b). 
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Fig. 5  A marker panel of five metabolites discriminates PDAC and 
CP. a Score scatter plot for the refined OPLS-DA model of the five 
discriminative metabolites with consistent fold-change directions in 
the validation cohort (Fig.  1, step 4b and 5). Orange dots represent 
PDAC samples (n = 20); white dots represent CP samples (n = 31); 
t1 on the x-axis, first component; to1 on the y-axis, first (and only) 
orthogonal component. Model parameters: CV-groups, 5; R2X(cum) 
0.736; Q2(cum) 0.513; CV-ANOVA p = 8.2E-07. b Corresponding 
loading scatter plot. All five metabolites in the marker panel show 
increased levels in PDAC compared to CP
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bile acids is tumor growth into the bile duct. Another the-
ory includes bile acid reflux into the pancreas, leading to 
pancreatitis and eventually malignant cell transformation; 
a direct carcinogenic effect of bile acids is also possible 
(Feng and Chen 2016). Bile acid levels in prediagnostic 
plasma have also been connected to future risk of pancre-
atic cancer (Mayers et al. 2014), supporting our results and 
reasoning.
Two of the discriminative metabolite markers identi-
fied here, N-palmitoyl glutamic acid and hexanoylcarni-
tine (Figs. 3, 5b), are fatty acid conjugates with an amino 
acid and carnitine, respectively. N-acyl amino acids were 
only recently discovered as a novel group of compounds 
and little is known about their function (Hanus et al. 2014). 
However, a recent study in mice showed that certain N-acyl 
amino acids regulate cell metabolism through mitochon-
drial uncoupling (Long et al. 2016). Acylcarnitines in turn 
are vital for the transport of fatty acids into the mitochon-
drial matrix (Indiveri et  al. 2011). Short-chain acylcarni-
tines including hexanoylcarnitine were previously found 
increased in serum in type 2 diabetes compared to normal 
glucose tolerance (Mai et  al. 2013); both CP and PDAC 
may cause diabetes (Pinho et al. 2014).
The levels of the nitrogenous metabolite PAGN were 
also increased in PDAC compared to CP in the present 
study (Fig. 5b). PAGN is a product of gut microbiota-host 
co-metabolism found in urine and blood (Barrios et  al. 
2015), and there are indications that the gut microbiota has 
an important role in carcinogenesis (Schwabe and Jobin 
2013).
In conclusion, this work has identified five metabolites 
capable of discriminating PDAC and CP in blood either as 
single or as a panel of markers. Findings were validated in 
a separate patient cohort. To determine the potential clini-
cal benefit of these markers, further evaluation in larger 
clinical studies is needed. Nevertheless, we believe that 
these metabolites are potentially useful for early diagnosis 
of PDAC in CP patients.
Acknowledgements A.N. acknowledges The Swedish Founda-
tion for Strategic Research (FFL4) and the Jane and Dan Olsson 
Foundation for funding. ML acknowledges ALF and Richard Julin 
Stiftelse for financial support and RH acknowledges Cancerfonden 
(CAN2008/982, CAN2013/780) for financial support.     The Swed-
ish Metabolomics Centre is acknowledged for support with LC-MS 
analysis.
Conflict of interest The authors declare that they have no conflict of 
interests in relation to the work described.
Ethical approval This study was approved by regional etic commit-
tee in Gothenburg, Sweden and by Die ethic-kommission-II, Fakultät 
für klinische Medizin Mannheim der Ruprecht-Karls-Universität Hei-
delberg, Germany, and was conducted in accordance with the 1964 
Helsinki declaration and its later amendments or comparable ethical 
standards.
Informed consent Blood samples were collected after informed 
consent from all patients.
Open Access This article is distributed under the terms of the 
Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted 
use, distribution, and reproduction in any medium, provided you give 
appropriate credit to the original author(s) and the source, provide a 
link to the Creative Commons license, and indicate if changes were 
made.
References
Barrios, C., M. Beaumont, T. Pallister, J. Villar, J. K. Goodrich, A. 
Clark, J. Pascual, R. E. Ley, T. D. Spector, J. T. Bell, C. Menni 
(2015). Gut-microbiota-metabolite axis in early renal func-
tion decline. Plos ONE 10(8), e0134311, doi:10.1371/journal.
pone.0134311.
Bylesjo, M., Rantalainen, M., Cloarec, O., Nicholson, J. K., Hol-
mes, E., & Trygg, J. (2006). OPLS discriminant analysis: 
Combining the strengths of PLS-DA and SIMCA classifica-
tion. Journal of Chemometrics, 20, 341–351. doi:10.1002/
cem.1006
Chechlinska, M., Kowalewska, M., & Nowak, R. (2010). Systemic 
inflammation as a confounding factor in cancer biomarker 
discovery and validation. Nature Reviews Cancer, 10, 2–13. 
doi:10.1038/nrc2782.
Daemen, A., Peterson, D., Sahu, N., McCord, R., Du, X., Liu, B., 
Kowanetz, K., Hong, R., Moffat, J., Gao, M., Boudreau, A., 
Mroue, R., Corson, L., O’Brien, T., Qing, J., Sampath, D., Mer-
chant, M., Yauch, R., Manning, G., Settleman, J., Hatzivassil-
iou, G., & Evangelista, M. (2015). Metabolite profiling stratifies 
pancreatic ductal adenocarcinomas into subtypes with distinct 
sensitivities to metabolic inhibitors. Proceedings of the National 
Academy of Sciences of the United States of America, 112, 
E4410–E4417. doi:10.1073/pnas.1501605112.
Davis, V. W., Schiller, D. E., Eurich, D., Bathe, O. F., & Sawyer, M. 
B. (2013). Pancreatic ductal adenocarcinoma is associated with 
a distinct urinary metabolomic signature. Annals of Surgical 
Oncology, 20, S415–S423. doi:10.1245/s10434-012-2686-7.
Denery, J. R., Nunes, A. A., & Dickerson, T. J. (2011). Characteri-
zation of differences between blood sample matrices in untar-
geted metabolomics. Analytical Chemistry, 83, 1040–1047. 
doi:10.1021/ac102806p.
Dunn, W. B., Broadhurst, D., Begley, P., Zelena, E., Francis-McIn-
tyre, S., Anderson, N., Brown, M., Knowles, J. D., Halsall, A., 
Haselden, J. N., Nicholls, A. W., Wilson, I. D., Kell, D. B., 
Goodacre, R., & Human Serum Metabolome, C. (2011). Pro-
cedures for large-scale metabolic profiling of serum and plasma 
using gas chromatography and liquid chromatography cou-
pled to mass spectrometry. Nature Protocols, 6, 1060–1083. 
doi:10.1038/nprot.2011.335.
Feng, H. Y., & Chen, Y. C. (2016). Role of bile acids in carcinogen-
esis of pancreatic cancer: An old topic with new perspective. 
World Journal of Gastroenterology, 22, 7463–7477. doi:10.3748/
wjg.v22.i33.7463.
Fiehn, O. (2002). Metabolomics–the link between genotypes and phe-
notypes. Plant molecular biology, 48, 155–171.
Fiehn, O., Kopka, J., Dormann, P., Altmann, T., Trethewey, R. 
N., & Willmitzer, L. (2000). Metabolite profiling for plant 
functional genomics. Nature Biotechnology, 18, 1157–1161. 
doi:10.1038/81137.
Discrimination of pancreatic cancer and pancreatitis by LC-MS metabolomics 
1 3
Page 9 of 10  61 
Fong, Z. V., & Winter, J. M. (2012). Biomarkers in pancreatic can-
cer diagnostic, prognostic, and predictive. Cancer Journal, 18, 
530–538. doi:10.1097/PPO.0b013e31827654ea.
Fukutake, N., M. Ueno, N. Hiraoka, K. Shimada, K. Shiraishi, N. 
Saruki, T. Ito, M. Yamakado, N. Ono, A. Imaizumi, S. Kikuchi, 
H. Yamamoto, K. Katayama (2015). A novel multivariate index 
for pancreatic cancer detection based on the plasma free amino 
acid profile. Plos ONE 10(7), e0132223. doi:10.1371/journal.
pone.0132223.
Garrido-Laguna, I., & Hidalgo, M. (2015). Pancreatic cancer: 
from state-of-the-art treatments to promising novel therapies. 
Nature Reviews. Clinical Oncology, 12, 319–334. doi:10.1038/
nrclinonc.2015.53.
Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next 
generation. Cell, 144, 646–674. doi:10.1016/j.cell.2011.02.013.
Hanus, L., Shohami, E., Bab, I., & Mechoulam, R. (2014). N-Acyl 
amino acids and their impact on biological processes. BioFac-
tors, 40, 381–388. doi:10.1002/biof.1166.
Indiveri, C., Iacobazzi, V., Tonazzi, A., Giangregorio, N., Infantino, 
V., Convertini, P., Console, L., & Palmieri, F. (2011). The mito-
chondrial carnitine/acylcarnitine carrier: Function, structure and 
physiopathology. Molecular Aspects of Medicine, 32, 223–233. 
doi:10.1016/j.mam.2011.10.008.
Ishikawa, M., Maekawa, K., Saito, K., Senoo, Y., Urata, M., Muray-
ama, M., Tajima, Y., Kumagai, Y., & Saito, Y. (2014). Plasma 
and serum lipidomics of healthy white adults shows characteris-
tic profiles by subjects’ gender and age. PLoS ONE, 9, e91806. 
doi:10.1371/journal.pone.0091806.
Kloppel, G., & Adsay, N. V. (2009). Chronic pancreatitis and the dif-
ferential diagnosis versus pancreatic cancer. archives of pathol-
ogy & laboratory. Medicine, 133, 382–387.
Kobayashi, T., S. Nishiumi, A. Ikeda, T. Yoshie, A. Sakai, A. Matsub-
ara, Y. Izumi, H. Tsumura, M. Tsuda, H. Nishisaki, N. Hayashi, 
S. Kawano, Y. Fujiwara, H. Minami, T. Takenawa, T. Azuma, M. 
Yoshida (2013). A novel serum metabolomics-based diagnostic 
approach to pancreatic cancer. Cancer Epidemiology Biomarkers 
& Prevention 22, 571–579 doi:10.1158/1055-9965.epi-12-1033.
Lindahl, A., Forshed, J., & Nordstrom, A. (2016). Overlap in serum 
metabolic profiles between non-related diseases: Implications 
for LC-MS metabolomics biomarker discovery. Biochemical 
and Biophysical Research Communications, 478, 1472–1477. 
doi:10.1016/j.bbrc.2016.08.155.
Lohr, J. M. (2014). Personal view Pancreatic cancer should be treated 
as a medical emergency. Bmj-British Medical Journal 349, 
g5261 doi:10.1136/bmj.g5261.
Lohr, M. (2006). Is it possible to survive pancreatic cancer? Nature 
clinical practice gastroenterology &amp. Hepatology, 3, 236–
237. doi:10.1038/ncpgasthep0469.
Long, J. Z., Svensson, K. J., Bateman, L. A., Lin, H., Kamenecka, T., 
Lokurkar, I. A., Lou, J., Rao, R. R., Chang, M. R., Jedrychowski, 
M. P., Paulo, J. A., Gygi, S. P., Griffin, P. R., Nomura, D. K., & 
Spiegelman, B. M. (2016). The secreted enzyme PM20D1 regu-
lates lipidated amino acid uncouplers of mitochondria. Cell, 166, 
424–435. doi:10.1016/j.cell.2016.05.071.
Mai, M., A. Tonjes, P. Kovacs, M. Stumvoll, G. M. Fiedler, A. B. 
Leichtle (2013). Serum levels of acylcarnitines are altered in pre-
diabetic conditions. Plos ONE 8(12), e82459. doi:10.1371/jour-
nal.pone.0082459.
Mayers, J. R., Wu, C., Clish, C. B., Kraft, P., Torrence, M. E., 
Fiske, B. P., Yuan, C., Bao, Y., Townsend, M. K., Tworoger, 
S. S., Davidson, S. M., Papagiannakopoulos, T., Yang, A., 
Dayton, T. L., Ogino, S., Stampfer, M. J., Giovannucci, E. 
L., Qian, Z. R., Rubinson, D. A., Ma, J., Sesso, H. D., Gazi-
ano, J. M., Cochrane, B. B., Liu, S. M., Wactawski-Wende, J., 
Manson, J. E., Pollak, M. N., Kimmelman, A. C., Souza, A., 
Pierce, K., Wang, T. J., Gerszten, R. E., Fuchs, C. S., Vander 
Heiden, M. G., & Wolpin, B. M. (2014). Elevation of circu-
lating branched-chain amino acids is an early event in human 
pancreatic adenocarcinoma development. Nature Medicine, 20, 
1193–1198. doi:10.1038/nm.3686.
Nicholson, J. K., Holmes, E., Kinross, J. M., Darzi, A. W., Takats, 
Z., & Lindon, J. C. (2012). Metabolic phenotyping in clinical 
and surgical environments. Nature, 491, 384–392. doi:10.1038/
nature11708.
Nordstrom, A., & Lewensohn, R. (2010). Metabolomics: Moving 
to the clinic. Journal of Neuroimmune Pharmacology, 5, 4–17. 
doi:10.1007/s11481-009-9156-4.
Patti, G. J., Yanes, O., & Siuzdak, G. (2012). Innovation: Metab-
olomics: The apogee of the omics trilogy. Nature Reviews. 
Molecular Cell Biology, 13, 263–269. doi:10.1038/nrm3314.
Pinho, A. V., Chantrill, L., & Rooman, I. (2014). Chronic pancrea-
titis: A path to pancreatic cancer. Cancer Letters, 345, 203–
209. doi:10.1016/j.canlet.2013.08.015.
Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Flesh-
man, J. M., & Matrisian, L. M. (2014). Projecting cancer 
incidence and deaths to 2030: The unexpected burden of 
thyroid, liver, and pancreas cancers in the United States. 
Cancer Research, 74, 2913–2921. doi:10.1158/0008-5472.
can-14-0155.
Rios Peces, S., Diaz Navarro, C., Marquez Lopez, C., Caba, O., Jime-
nez-Luna, C., Melguizo, C., Prados, J. C., Genilloud, O., Vicente 
Perez, F., & Perez Del Palacio, J. (2016). Untargeted LC-HRMS-
based metabolomics for searching new biomarkers of pancreatic 
ductal adenocarcinoma: A pilot study. Journal of biomolecular 
screening: the official journal of the Society for Biomolecular 
Screening. doi:10.1177/1087057116671490.
Ritchie, S. A., H. Akita, I. Takemasa, H. Eguchi, E. Pastural, H. 
Nagano, M. Monden, Y. Doki, M. Mori, W. Jin, T. T. Sajobi, D. 
Jayasinghe, B. Chitou, Y. Yamazaki, T. White, D. B. Goodenowe 
(2013). Metabolic system alterations in pancreatic cancer patient 
serum: potential for early detection. Bmc Cancer 13(1), 416. 
doi:10.1186/1471-2407-13-416.
Sakai, A., Suzuki, M., Kobayashi, T., Nishiumi, S., Yamanaka, K., 
Hirata, Y., Nakagawa, T., Azuma, T., & Yoshida, M. (2016). 
Pancreatic cancer screening using a multiplatform human serum 
metabolomics system. Biomarkers in Medicine, 10, 577–586. 
doi:10.2217/bmm-2016-0020.
Schwabe, R. F., & Jobin, C. (2013). The microbiome and cancer. 
Nature Reviews Cancer, 13, 800–812. doi:10.1038/nrc3610.
Siegel, R. L., K. D. Miller, A. Jemal (2016). Cancer statistics, 2016. 
Ca-a Cancer Journal for Clinicians 66, 7–30. doi:10.3322/
caac.21332.
Smith, C. A., O’Maille, G., Want, E. J., Qin, C., Trauger, S. A., Bran-
don, T. R., Custodio, D. E., Abagyan, R., & Siuzdak, G. (2005). 
METLIN: A metabolite mass spectral database. Therapeutic 
drug monitoring, 27, 747–751.
Smith, C. A., Want, E. J., O’Maille, G., Abagyan, R., & Siuzdak, G. 
(2006). XCMS: Processing mass spectrometry data for metabo-
lite profiling using nonlinear peak alignment, matching, and 
identification. Analytical Chemistry, 78, 779–787. doi:10.1021/
ac051437y.
Spratlin, J. L., Serkova, N. J., & Eckhardt, S. G. (2009). Clinical 
applications of metabolomics in oncology: a review. Clinical 
cancer research: an official journal of the American Associa-
tion for Cancer Research, 15, 431–440. doi:10.1158/1078-0432.
CCR-08-1059.
Staubert, C., Bhuiyan, H., Lindahl, A., Broom, O. J., Zhu, Y. F., 
Islam, S., Linnarsson, S., Lehtio, J., & Nordstrom, A. (2015). 
Rewired metabolism in drug-resistant leukemia cells a meta-
bolic switch hallmarked by reduced dependence on exogenous 
glutamine. Journal of Biological Chemistry, 290, 8348–8359. 
doi:10.1074/jbc.M114.618769.
 A. Lindahl et al.
1 3
61  Page 10 of 10
Trezzi, J. P., Vlassis, N., & Hiller, K. (2015). The role of metabo-
lomics in the study of cancer biomarkers and in the development 
of diagnostic tools. Advances in Experimental Medicine and 
Biology, 867, 41–57. doi:10.1007/978-94-017-7215-0_4.
Urayama, S., Zou, W., Brooks, K., & Tolstikov, V. (2010). Compre-
hensive mass spectrometry based metabolic profiling of blood 
plasma reveals potent discriminatory classifiers of pancreatic 
cancer. Rapid Communications in Mass Spectrometry, 24, 613–
620. doi:10.1002/rcm.4420.
van der Hooft, J. J. J., Vervoort, J., Bino, R. J., & R. C. H. de Vos 
(2012). Spectral trees as a robust annotation tool in LC-MS 
based metabolomics. Metabolomics, 8, 691–703. doi:10.1007/
s11306-011-0363-7.
Wang, T. J., Larson, M. G., Vasan, R. S., Cheng, S., Rhee, E. P., 
McCabe, E., Lewis, G. D., Fox, C. S., Jacques, P. F., Fernandez, 
C., O’Donnell, C. J., Carr, S. A., Mootha, V. K., Florez, J. C., 
Souza, A., Melander, O., Clish, C. B., & Gerszten, R. E. (2011). 
Metabolite profiles and the risk of developing diabetes. Nature 
Medicine, 17, 448–483. doi:10.1038/nm.2307.
Want, E. J., Nordstrom, A., Morita, H., & Siuzdak, G. (2007). From 
exogenous to endogenous: the inevitable imprint of mass spec-
trometry in metabolomics. Journal of Proteome Research 6, 459–
468 doi:10.1021/pr060505+.
Wingren, C., Sandstrom, A., Segersvard, R., Carlsson, A., Anders-
son, R., Lohr, M., & C. A. K. Borrebaeck (2012). Identification 
of serum biomarker signatures associated with pancreatic can-
cer. Cancer Research, 72, 2481–2490. doi:10.1158/0008-5472.
can-11-2883.
Wishart, D. S., Jewison, T., Guo, A. C., Wilson, M., Knox, C., Liu, Y. 
F., Djoumbou, Y., Mandal, R., Aziat, F., Dong, E., Bouatra, S., 
Sinelnikov, I., Arndt, D., Xia, J. G., Liu, P., Yallou, F., Bjorndahl, 
T., Perez-Pineiro, R., Eisner, R., Allen, F., Neveu, V., Greiner, 
R., & Scalbert, A. (2013). HMDB 3.0-The human metabolome 
database in 2013. Nucleic Acids Research, 41, D801–D807. 
doi:10.1093/nar/gks1065.
World Med A. (2013). World medical association declaration of hel-
sinki ethical principles for medical research involving human 
subjects. Jama-Journal of the American Medical Association 
310, 2191–2194 doi:10.1001/jama.2013.281053.
Yin, P., & Xu, G. (2014). Current state-of-the-art of nontargeted 
metabolomics based on liquid chromatography-mass spec-
trometry with special emphasis in clinical applications. 
Journal of chromatography. A, 1374, 1–13. doi:10.1016/j.
chroma.2014.11.050.
Yu, Z. H., G. Kastenmuller, Y. He, P. Belcredi, G. Moller, C. Prehn, 
J. Mendes, S. Wahl, W. Roemisch-Margl, U. Ceglarek, A. Polon-
ikov, N. Dahmen, H. Prokisch, L. Xie, Y. X. Li, H. E. Wich-
mann, A. Peters, F. Kronenberg, K. Suhre, J. Adamski, T. Illig, 
R. Wang-Sattler (2011). Differences between human plasma 
and serum metabolite profiles. Plos ONE. doi:10.1371/journal.
pone.0021230.
Zhang, L., Jin, H. F., Guo, X. G., Yang, Z., Zhao, L., Tang, S. H., 
Mo, P., Wu, K. C., Nie, Y. Z., Pan, Y. L., & Fan, D. M. (2012). 
Distinguishing pancreatic cancer from chronic pancreatitis and 
healthy individuals by H-1 nuclear magnetic resonance-based 
metabonomic profiles. Clinical Biochemistry, 45, 1064–1069. 
doi:10.1016/j.clinbiochem.2012.05.012.
